Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6455216 | 0.79 | DHFR (1.00) | DHFRCYP2D6 | |
| Hydrochloric Acid SCHEMBL8986147 | 0.78 | CYP2D6 (0.74) | DHFRCYP2D6 | |
| SCHEMBL14577668 | 0.78 | DHFR (0.73) | DHFRCYP2D6 | |
| SCHEMBL29449854 | 0.75 | NCOA3 (1.00) | DHFRCYP2D6 | |
| SCHEMBL6456167 | 0.75 | NCOA3 (1.00) | DHFRCYP2D6 | |
| SCHEMBL670885 | 0.75 | DHFR (1.00) | DHFR | |
| SCHEMBL8738472 | 0.74 | CYP2D6 (1.00) | CYP2D6 | |
| Chlorcycloguanil SCHEMBL8986158 | 0.74 | DHFR (1.00) | DHFR | |
| SCHEMBL14577773 | 0.73 | GAA (0.72) | CYP2D6 | |
| SCHEMBL669929 | 0.73 | DHFR (0.73) | DHFRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203908-A1 | Dihydrofolate reductase inhibitors | ISIS INNOVATION LIMITED (GB) | 2003-10-30 | — | — | US | claimed |
| WO-2001053276-A1 | DIHYDROFOLATE REDUCTASE INHIBITORS | ISIS INNOVATION LIMITED (GB) | 2001-07-26 | — | — | WO | claimed |
| US-20030203908-A1 | Dihydrofolate reductase inhibitors | ISIS INNOVATION LIMITED (GB) | 2003-10-30 | — | — | US | disclosed |
| WO-2001053276-A1 | DIHYDROFOLATE REDUCTASE INHIBITORS | ISIS INNOVATION LIMITED (GB) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203908-A1 | Dihydrofolate reductase inhibitors | DHFR, CBR1, GRHPR | DHFR 1/4885CYP2D6 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.